Efficacy of NuvaRing

The efficacy of NuvaRing has been established in women aged between 18 and 40 years.1 When used as directed, NuvaRing is more than 99% effective at preventing pregnancy. This high rate of contraceptive efficacy is comparable to the use of combined oral contraceptives (COCs).1,3,4

In clinical trials, NuvaRing has been shown to have a low Pearl Index (see Table below) that is similar to COCs.1,3,4 The Pearl Index is a measure of the number of pregnancies that occur for every 100 women years of use, with lower numbers indicating fewer pregnancies.

Efficacy of NuvaRing as compared with COCs3,4

†NuvaRing compared with 30 µg ethinylestradiol (EE) plus drospirenone COC; †NuvaRing compared with 15 µg (EE) plus 120 µg levonorgestrel COC; ITT, intention-to-treat; PP, per protocol

 

 

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.gov.uk.
Adverse events should also be reported to MSD Drug Safety Department on 01707 363773

Organon

Expiry 10/11 - NUV.10.GB.27040.AV

© 2010 Copyright Organon Laboratories Limited. All rights reserved.

Terms and Conditions
Privacy Policy


© 2010 Organon Laboratories Ltd trading as MSD: Registered Address: Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU.
A company registered in England and Wales. Company Registration Number: 820771